Nurexone receives $3.18-million from warrant exercise

Executive Summary

• Nurexone Biologic Inc. received gross proceeds of over C$3.18 million ($3,185,994.43 CAD) through the accelerated exercise of outstanding warrants.
• The capital raise was triggered by acceleration notices issued on Oct. 8, 2025, following the company's common shares meeting specific daily volume average trading price thresholds for 20 consecutive trading days.
• The funds are designated for general corporate purposes, working capital, and the continued development of the company's exosome-based therapeutic platform, specifically supporting the advancement of ExoPTEN.

Key Details

• Total Gross Proceeds: $3,185,994.43 CAD.
• Tranche 1 (September 2023 Warrants):
  • Proceeds: $1,207,418.88 CAD.
  • Warrants Exercised: 2,515,456.
  • Exercise Price: $0.48 CAD per warrant.
  • Original Issuance: Non-brokered private placement closed in tranches on Aug. 25, 2023, and Sept. 6, 2023.
  • Acceleration Trigger: Daily volume average trading price of common shares on the TSX-V equaled or exceeded $0.83 CAD for 20 consecutive trading days.
• Tranche 2 (January 2024 Warrants):
  • Proceeds: $1,978,575.55 CAD.
  • Warrants Exercised: 5,653,073.
  • Exercise Price: $0.35 CAD per warrant.
  • Original Issuance: Non-brokered private placement closed on Jan. 4, 2024.
  • Acceleration Trigger: Daily volume average trading price of common shares on the TSX-V equaled or exceeded $0.80 CAD for 20 consecutive trading days.
• Use of Proceeds: General corporate purposes, working capital, and supporting the continuing development of the exosome-based therapeutic platform.
• Additional Corporate Updates:
  • Nurexone was named a finalist for the Galien Foundation's inaugural Prix Galien Bridges Awards (event in Stockholm, Dec. 5, 2025).
  • Nurexone was recognized as a finalist in the Falling Walls Science Breakthroughs of the Year Summit in Berlin.

Notable Quotes

• Dr. Lior Shaltiel, CEO: "We are very pleased with the full participation from warrantholders during the accelerated exercise period... This additional capital enhances our financial strengths as we continue advancing ExoPTEN and our therapeutic pipeline towards clinical readiness."
• Eran Ovadya, CFO: "The full participation of these warrantholders reflects investor confidence in Nurexone's strategy and our exosome-based platform. The resulting funds provide further financial stability, enabling us to efficiently allocate resources towards clinical development and key operational priorities, while maintaining a strong balance sheet."
• Dr. Tali Kizhner, Director of R&D: "Our recognition among leading innovators in Europe, from Prix Galien in Stockholm to Falling Walls in Berlin, highlights our growing leadership position in exosome-based medicine... We are proud to represent a new wave of regenerative biotechnology with the potential to connect scientific excellence with tangible human impact."